Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matrixx Decision Raises More Disclosure Questions – Law Professor

This article was originally published in The Tan Sheet

Executive Summary

The Supreme Court's decision in the lawsuit alleging Matrixx Initiatives fraudulently withheld adverse event reports from investors provides little guidance for pharmaceutical and dietary supplement firms on disclosing adverse events, an expert says.
Advertisement

Related Content

FDLI Conference In Brief
FDLI Conference In Brief
Supreme Court's Matrixx Decision Expands Firms' Disclosure Burden
Supreme Court's Matrixx Decision Expands Firms' Disclosure Burden
Search For Balance Drives Supreme Court Debate In Matrixx Case
Matrixx Case Is Already Shaping Disclosure Strategies – Experts

Topics

Advertisement
UsernamePublicRestriction

Register

PS104982

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel